EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library Reference physiology and guidance Peer-reviewed human data Schematics and calculations

The kidney

How the kidneys filter blood, reclaim most of what they filter and secrete drugs into the urine; how kidney function is measured and staged; which hormones the kidney makes; and which supplement effects on the kidney have been documented in people.

19%of resting cardiac output flows to the kidneys in the ICRP reference adult male (17% in the female)
≈180 Lof plasma filtered per day: a glomerular filtration rate of about 125 mL/min in a middle-aged man
0.7%of the filtrate leaves as urine; the tubules reabsorb the rest
≈1 millionnephrons in each kidney

ICRP Publication 89 (2002), Tables 2.39 and 2.40 and paragraphs 329, 380 and 383.

Status. Education, not medical advice. Figures marked as calculations are educational calculations from published equations, not measurements and not predictions for any person, product or ingredient. Reference ranges for laboratory tests vary by laboratory.

Related: ADME, PK and PBPK · Contaminants · Lessons learned

Three-dimensional rendering of a nephron: a glomerulus inside Bowman’s capsule, the proximal tubule, the loop of Henle, the distal tubule and the collecting duct.
  1. 1 Glomerulus in Bowman’s capsule: blood is filtered
  2. 2 Proximal tubule: most water and solutes reabsorbed
  3. 3 Loop of Henle
  4. 4 Distal tubule
  5. 5 Collecting duct

Rendered by EUTECNIQ; generalized and not to scale.

Anatomy

Each nephron filters plasma, then its tubule takes most of the filtrate back

Each kidney has an outer cortex and an inner medulla and holds about one million nephrons. A nephron starts at the renal corpuscle, where a tuft of glomerular capillaries sits inside Bowman's capsule. Its tubule then runs through the proximal tubule, the loop of Henle and the distal convoluted tubule before draining into a collecting duct.

Blood reaches the glomerulus through the afferent arteriole and leaves through the efferent arteriole, which feeds a second capillary bed around the tubules. Those peritubular capillaries take up what the tubules reabsorb. At the glomerulus's vascular pole, macula densa cells in the tubule wall sense the salt content of the tubular fluid; with the two arterioles and the extraglomerular mesangium they form the juxtaglomerular apparatus.

Seven segments, each with a different job: the proximal tubule reclaims most, the collecting duct sets the final urineSchematic with published values
Schematic of a long-looped nephron and its collecting duct across the renal cortex, outer medulla and inner medulla, with seven numbered segments and what each reabsorbs or secretesCortexOuter medullaInner medullaAfferentarterioleEfferentarterioleto the renal pelvis12345671Renal corpuscleGlomerular capillaries inside Bowman's capsule.Filtration ≈125 mL/min, ≈180 L/day in a middle-agedman; solutes under ≈5,000 Da pass unless bound toprotein.2Proximal tubuleReabsorbs ≈65% of the filtrate, 65–70% of filteredNa+​ and ≈90% of filtered glucose (SGLT2). Secretesdrugs and creatinine (OAT1, OAT3, OCT2, MATEs).3Thin limbs of the loopThe descending limb is highly permeable to water butnot to solutes, so the fluid concentrates toward the tipof the loop.4Thick ascending limbReabsorbs 20–25% of filtered Na+​ through NKCC2but is impermeable to water, so it dilutes the tubularfluid. The whole loop takes back ≈15% of the filtrate.5Macula densaSenses low NaCl in the tubular fluid and signals reninrelease from juxtaglomerular cells at the tip of theafferent arteriole.6Distal convoluted tubuleReabsorbs 5–7% of filtered Na+​ through NCC, thethiazide target.7Connecting tubule, collecting duct2–5% of filtered Na+​ via ENaC under aldosterone; K+​secretion. Aquaporin-2, moved to the membraneunder vasopressin, lets water leave; urine can reach≈1,400 mosmol/L.Schematic, not to scale. Long-looped (juxtamedullary) nephron.Schematic of a long-looped nephron and its collecting duct across the renal cortex, outer medulla and inner medulla, with seven numbered segments and what each reabsorbs or secretesCortexOuter medullaInner medullaAfferentarterioleEfferentarterioleto the renal pelvis12345671Renal corpuscleGlomerular capillaries inside Bowman's capsule.Filtration ≈125 mL/min, ≈180 L/day in a middle-agedman; solutes under ≈5,000 Da pass unless bound toprotein.2Proximal tubuleReabsorbs ≈65% of the filtrate, 65–70% of filteredNa+​ and ≈90% of filtered glucose (SGLT2). Secretesdrugs and creatinine (OAT1, OAT3, OCT2, MATEs).3Thin limbs of the loopThe descending limb is highly permeable to water butnot to solutes, so the fluid concentrates toward thetip of the loop.4Thick ascending limbReabsorbs 20–25% of filtered Na+​ through NKCC2but is impermeable to water, so it dilutes the tubularfluid. The whole loop takes back ≈15% of the filtrate.5Macula densaSenses low NaCl in the tubular fluid and signals reninrelease from juxtaglomerular cells at the tip of theafferent arteriole.6Distal convoluted tubuleReabsorbs 5–7% of filtered Na+​ through NCC, thethiazide target.7Connecting tubule, collecting duct2–5% of filtered Na+​ via ENaC under aldosterone; K+​secretion. Aquaporin-2, moved to the membraneunder vasopressin, lets water leave; urine can reach≈1,400 mosmol/L.Schematic, not to scale. Long-looped (juxtamedullary) nephron.
Schematic, not to scale. Anatomy and filtrate shares: ICRP Publication 89 (2002), paragraphs 329–334, 380–383. Sodium shares by segment: Gembillo et al., J Pers Med 2026;16:466 (citing Ellison, Clin J Am Soc Nephrol 2019, for the proximal tubule, thick ascending limb and collecting duct shares). Glucose: Gembillo et al. 2026. Thin and thick limbs: Zacchia et al., Int J Nephrol Renovasc Dis 2018;11:81–92. Renin release and the macula densa: Yamaguchi et al., Hypertension 2023;80:1580–1589. Aquaporin-2 and vasopressin: UniProt P41181. Maximal urine concentration: ICRP 89, paragraph 125.
Text version of the drawing: the seven numbered segments
  1. Renal corpuscleGlomerular capillaries inside Bowman's capsule, fed by the afferent arteriole and drained by the efferent arteriole. Filtration is about 125 mL/min (about 180 L/day) in a middle-aged man; solutes under about 5,000 Da are freely filtered unless bound to plasma proteins.
  2. Proximal tubuleConvoluted and straight parts. Reabsorbs about 65% of the filtrate, 65–70% of filtered sodium and about 90% of filtered glucose (through SGLT2). Secretes organic anions, organic cations and creatinine.
  3. Thin limbs of the loop of HenleThe descending limb penetrates the medulla and is highly permeable to water but not to solutes, so luminal osmolality rises toward the tip of the loop.
  4. Thick ascending limbReabsorbs 20–25% of filtered sodium through NKCC2 and is impermeable to water, so it dilutes the tubular fluid. The loop as a whole reabsorbs about 15% of the filtrate.
  5. Macula densaCells at the glomerular vascular pole, part of the juxtaglomerular apparatus. A fall in NaCl concentration in the tubular fluid signals renin release.
  6. Distal convoluted tubuleReabsorbs 5–7% of filtered sodium through the Na–Cl cotransporter NCC.
  7. Connecting tubule and collecting ductReabsorb 2–5% of filtered sodium through ENaC under aldosterone and secrete potassium. Aquaporin-2 water channels, moved to the cell membrane under vasopressin, let water follow the medullary osmotic gradient; urine can reach about 1,400 mosmol/L.
What each nephron segment reabsorbs or secretes, with the main transport proteins and the source of each value
SegmentReabsorbsSecretesMain transport proteins
Proximal tubule≈65% of the filtrate; 65–70% of filtered Na+; ≈90% of filtered glucose; ≈65% of filtered K+Organic anions and cations, including many drugs; creatinineNHE3 (Na+/H+ exchange), SGLT2; OAT1, OAT3, OCT2, MATE1, MATE2-K, P-gp, BCRP
Thin descending limbWater—Water-permeable epithelium
Thick ascending limb20–25% of filtered Na+; ≈25% of filtered K+ (ICRP's “diluting segment”)—NKCC2; ROMK K+ channel
Distal convoluted tubule5–7% of filtered Na+—NCC
Connecting tubule, collecting duct2–5% of filtered Na+; water when vasopressin is presentK+, increased by aldosteroneENaC; aquaporin-2

Filtrate and potassium: ICRP Publication 89, paragraphs 383 and 389–391 (the potassium figure of 25% is given for the "diluting segment"). Sodium: Gembillo et al. 2026. NHE3: Zheng and Layton, Front Physiol 2026;17:1828410. Glucose, NKCC2, ROMK, NCC, ENaC: Gembillo et al. 2026. Thin limbs: Zacchia et al. 2018. Drug transporters: section 4. Published shares are rounded, come from different sources and need not add to 100%.

Blood flow and filtration

About a fifth of cardiac output passes through 310 grams of kidney

Renal blood flow is about 4 mL per gram of tissue per minute, far above most organs. About 18% of the plasma entering the kidneys is filtered; this ratio of GFR to renal plasma flow is the filtration fraction. Kidney transport work uses about 8% of the body's total oxygen consumption.

ICRP Publication 89 reference values for the kidneys
QuantityValueICRP 89 location
Mass of both kidneys310 g (adult male); 275 g (adult female)Table 2.8
Renal blood flow19% of cardiac output, male; 17%, female. With cardiac output 6.5 and 5.9 L/min: 1.24 and 1.00 L/min (computed)Tables 2.39, 2.40
PerfusionAbout 4 mL blood per g tissue per minParagraph 378
Glomerular filtration rateAbout 125 mL/min, about 180 L/day (middle-aged adult male); lower on average in females; declines with ageParagraph 380
Renal plasma flow; filtration fractionAbout 700 mL/min (young adult male); FF = GFR/RPF ≈ 0.18Paragraph 380
Freely filtered solutesMolecular mass under 5,000 Da, except those bound to plasma proteins; about half of plasma calcium is protein-boundParagraph 381
Urine volumeTypically 1,200–2,000 mL/day; reference 1,600 mL/day (male), 1,200 mL/day (female)Paragraph 385, Table 2.41
Maximal urine concentrationAbout 1,400 mosmol/L; obligatory urine about 0.5 L/dayParagraph 125
Kidney blood content2.0% of total blood volumeTable 2.14

ICRP, 2002. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. ICRP Publication 89. Organ blood flows for physiologically based models are tabulated on ADME, PK and PBPK.

The proximal tubule reclaims about two thirds of both water and sodium; the distal segments fine-tune what is leftICRP 89 and peer-reviewed values
Share of the glomerular filtrate and of filtered sodium reabsorbed in each nephron segmentFiltrate (water), ICRP Publication 89Filtered Na+​, published rangeProximal tubuleProximal tubule: 65% of the filtrate reabsorbed (ICRP 89)65%65–70% of Na+​Loop of HenleLoop of Henle: 15% of the filtrate reabsorbed (ICRP 89)15%20–25% of Na+​ (thick limb)Distal tubuleDistal tubule: 10% of the filtrate reabsorbed (ICRP 89)10%5–7% of Na+​ (DCT)Collecting ductCollecting duct: 9.3% of the filtrate reabsorbed (ICRP 89)9.3%2–5% of Na+​Excreted in urineExcreted in urine: 0.7% of the filtrate excreted (ICRP 89)0.7%≈1% of Na+​0%20%40%60%80%Percent of the filtered loadShare of the glomerular filtrate and of filtered sodium reabsorbed in each nephron segmentFiltrate (water), ICRP 89Filtered Na+​, rangeProximal tubuleProximal tubule: 65% of the filtrate reabsorbed (ICRP 89)65%65–70% of Na+​Loop of HenleLoop of Henle: 15% of the filtrate reabsorbed (ICRP 89)15%20–25% of Na+​ (thick limb)Distal tubuleDistal tubule: 10% of the filtrate reabsorbed (ICRP 89)10%5–7% of Na+​ (DCT)Collecting ductCollecting duct: 9.3% of the filtrate reabsorbed (ICRP 89)9.3%2–5% of Na+​Excreted in urineExcreted in urine: 0.7% of the filtrate excreted (ICRP 89)0.7%≈1% of Na+​0%20%40%60%80%Percent of the filtered load
Filtrate (water): ICRP Publication 89, paragraph 383 ("proximal tubules, 65%; loop of Henle, 15%; distal tubules, 10%; collecting ducts, 9.3%"; 0.7% excreted). Sodium: Gembillo et al., J Pers Med 2026 (proximal tubule 65–70%, thick ascending limb 20–25%, distal convoluted tubule 5–7%, collecting duct 2–5%); about 1% excreted: Zheng and Layton, Front Physiol 2026.
Show data: share of the filtered load reabsorbed per segment
Percent of the filtrate and of filtered sodium reabsorbed in each segment
SegmentFiltrate (water), %Filtered Na+, %
Proximal tubule6565–70
Loop of Henle (Na+: thick ascending limb)1520–25
Distal tubule (Na+: distal convoluted tubule)105–7
Collecting duct9.32–5
Excreted in urine0.7about 1
Amounts filtered and excreted per minute at a GFR of 125 mL/min and a urine flow of 1.1 mL/min
SubstanceFiltered per minuteExcreted in urine per minute
Sodium18 mEq0.14 mEq
Potassium0.63 mEq0.066 mEq
Glucose125 mg0 mg
Urea31 mg18 mg
Uric acid3.8 mg0.42 mg
Creatinine1.4 mg1.2 mg

ICRP Publication 89, Table 8.3 (modified from Guyton, 1982), assuming GFR 125 mL/min and urine flow 1.1 mL/min. ICRP gives about 60% of filtered urea and about 15% of filtered urate as excreted (paragraphs 400–401). These are textbook reference values, not measurements in one person.

Clearance

Renal clearance adds filtration and secretion and subtracts reabsorption

Renal clearance is the volume of plasma the kidneys free of a substance per unit time. Only the unbound fraction of a drug in plasma is filtered, so filtration clearance is fu × GFR. A renal clearance clearly above that value means the tubules secrete the compound; a value below it means net reabsorption. The general pharmacokinetic equations are on ADME, PK and PBPK.

Renal clearance equations and regulatory thresholds
QuantityEquation or criterionSource
Renal (urinary) clearanceCLR = (U × V̇) / P: urine concentration times urine flow rate, divided by plasma concentrationProvenzano et al., J Nephrol 2024
Filtration fractionFF = GFR / RPFICRP 89, paragraph 380
Filtration clearance of a drugCLGF = fu × GFRCristea et al., AAPS J 2020
Active secretion clearance (no reabsorption assumed)CLR − fu,p × GFRICH M12, section 2.2.1
Model with filtration and active secretionCLR = fu·GFR + (QR − GFR)·fu·CLint,sec / (QR + fu·CLint,sec/B:P)Cristea et al. 2020 (no passive reabsorption or renal metabolism)
Secretion indicatedCLR > 1.5 × fu × GFR (assume fu = 0.01 if binding exceeds 99.9% or is unknown)International Transporter Consortium, Giacomini et al. 2010
Test as renal transporter substrateActive renal secretion ≥ 25% of systemic clearance: study OAT1, OAT3, OCT2, MATE1 and MATE2-K in vitroICH M12, section 2.2.1
Dedicated renal impairment studyFraction of systemically available drug or active metabolite excreted unchanged in urine ≥ 0.3FDA guidance, March 2024
eGFR in mL/min for dosingeGFR (mL/min) = eGFR (mL/min/1.73 m²) × BSA / 1.73FDA guidance, March 2024

Provenzano M, et al. J Nephrol 2024;37:573–586; Cristea S, et al. AAPS J 2020;22:87; ICH M12 Drug Interaction Studies, adopted May 21, 2024 (issued by FDA as final guidance, docket FDA-2022-D-1527); Giacomini KM, et al. Nat Rev Drug Discov 2010;9:215–236; FDA, Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing, guidance for industry, March 2024.

Secretion can lift renal clearance from fu·GFR toward renal blood flow; protein binding delays the climbCalculation
Renal clearance against secretory intrinsic clearance for fraction unbound 1, 0.5 and 0.1, calculated with renal blood flow 74.1 L/h and GFR 7.5 L/h020406080Renal clearance CLR​, L/h0.11101001,00010,000Secretory intrinsic clearance CLint,sec​, L/hf_{u} = 1f_{u} = 0.5f_{u} = 0.1renal blood flow QR​ = 74.1 L/hGFR = 7.5 L/hfu​ = 1fu​ = 0.5fu​ = 0.1Blood-to-plasmaratio set to 1Renal clearance against secretory intrinsic clearance for fraction unbound 1, 0.5 and 0.1, calculated with renal blood flow 74.1 L/h and GFR 7.5 L/h020406080Renal clearance CLR​, L/h0.1110102​103​104​Secretory intrinsic clearance CLint,sec​, L/hf_{u} = 1f_{u} = 0.5f_{u} = 0.1renal blood flow QR​ = 74.1 L/hGFR = 7.5 L/hfu​ = 1fu​ = 0.5fu​ = 0.1Blood-to-plasma ratio set to 1
Calculated from the Cristea et al. (AAPS J 2020) model with parameters from ICRP Publication 89: QR = 6.5 L/min × 19% × 60 = 74.1 L/h, GFR = 125 mL/min = 7.5 L/h (adult male); blood-to-plasma ratio set to 1 as a stated assumption. An educational calculation, not a measurement or a prediction for any product.
Show data: calculated renal clearance, L/h
Calculated renal clearance at six secretory intrinsic clearances for three unbound fractions
CLint,sec, L/hfu = 1fu = 0.5fu = 0.1
0.17.63.80.8
18.44.20.8
1015.48.01.6
10045.830.68.7
1,00069.561.839.0
10,00073.669.462.8
Transporters

Uptake transporters on the blood side and efflux transporters on the urine side move drugs through the proximal tubule

Active secretion is a two-step relay through the proximal tubule cell. OAT1, OAT3 and OCT2 take compounds up from blood across the basolateral membrane; MATE1, MATE2-K and the ATP-driven pumps P-gp and BCRP push them into the urine across the apical brush border. URAT1 works the other way, reabsorbing urate from the urine.

Regulators ask drug developers to test new drugs against these transporters. ICH M12 asks for inhibition studies on P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1 and MATE2-K. OATP4C1 and URAT1 are not on that list; they appear in the International Transporter Consortium's map of the proximal tubule.

Four uptake transporters face the blood, four efflux transporters face the urine, and URAT1 brings urate backSchematic of published localizations
A proximal tubule cell with drug transporters: OAT1, OAT3, OCT2 and OATP4C1 take up compounds from blood at the basolateral membrane; MATE1, MATE2-K, P-gp and BCRP move them into the urine at the apical membrane; URAT1 reabsorbs urate from the urineBlood sideperitubular capillaryTubular lumenurine sideProximal tubule cellbasolateral membraneapical membrane, brush borderOAT1 · SLC22A6p-aminohippurate, tenofovirOAT3 · SLC22A8benzylpenicillin, methotrexateOCT2 · SLC22A2metformin, creatinineOATP4C1 · SLCO4C1digoxin, thyroid hormonesMATE1 · SLC47A1metformin, creatinineMATE2-K · SLC47A2metformin, creatinineP-gp · ABCB1digoxin, fexofenadineBCRP · ABCG2rosuvastatin, sulfasalazineURAT1 · SLC22A12urate, reabsorbedorganic anion uptakeorganic cationATP-driven effluxurate reabsorptionSchematic, not to scaleA proximal tubule cell with drug transporters: four uptake transporters at the basolateral (blood) membrane, four efflux transporters at the apical (urine) membrane and URAT1 reabsorbing urateBlood sideUrine side (lumen)Proximal tubule cellOAT1 · SLC22A6p-aminohippurate, tenofovirOAT3 · SLC22A8benzylpenicillin, methotrexateOCT2 · SLC22A2metformin, creatinineOATP4C1 · SLCO4C1digoxin, thyroid hormonesMATE1 · SLC47A1metformin, creatinineMATE2-K · SLC47A2metformin, creatinineP-gp · ABCB1digoxin, fexofenadineBCRP · ABCG2rosuvastatin, sulfasalazineURAT1 · SLC22A12urate, reabsorbedorganic anion uptakeorganic cationATP-driven effluxurate reabsorptionSchematic, not to scale
Schematic, not to scale. Localization: International Transporter Consortium, Giacomini et al., Nat Rev Drug Discov 2010, Fig. 1c; BCRP in the proximal tubule brush border: Huls et al., Kidney Int 2008;73:220–225; UniProt entries Q4U2R8, Q8TCC7, O15244, Q6ZQN7, Q96FL8, Q86VL8, P08183, Q9UNQ0, Q96S37 (retrieved October 29, 2026). Example substrates: FDA in vitro substrate table (content current June 5, 2023); OATP4C1 and URAT1 substrates from UniProt.
Nine kidney drug transporters with gene, membrane, direction and FDA example substrates and inhibitors
TransporterGeneMembrane and directionExample substratesExample inhibitors
OAT1SLC22A6Basolateral; blood into cellAdefovir, p-aminohippurate, cidofovir, tenofovir (in vitro)Probenecid, benzylpenicillin (in vitro, OAT1/OAT3)
OAT3SLC22A8Basolateral; blood into cellBenzylpenicillin, estrone-3-sulfate, methotrexate, pravastatin (in vitro); clinical: furosemide, methotrexateProbenecid (clinical, OAT1/OAT3)
OCT2SLC22A2Basolateral; blood into cellCreatinine, metformin, tetraethylammonium (in vitro)Cimetidine, clonidine (in vitro); clinical: cimetidine, dolutegravir
OATP4C1SLCO4C1Basolateral in the ITC map; blood into cell (UniProt instead describes an apical uptake role, inferred by similarity)Digoxin, ouabain, methotrexate, thyroid hormones T3 and T4 (UniProt)Not listed by FDA
MATE1SLC47A1Apical (brush border); cell into urine, in exchange for H+Creatinine, metformin, MPP+, tetraethylammonium (in vitro)Cimetidine, pyrimethamine (in vitro); clinical: trimethoprim, pyrimethamine
MATE2-KSLC47A2Apical (brush border); cell into urine, in exchange for H+As MATE1 (in vitro)As MATE1
P-gpABCB1Apical; cell into urine, ATP-drivenDigoxin, fexofenadine, loperamide, quinidine (in vitro)Cyclosporine, ketoconazole, quinidine, verapamil (in vitro)
BCRPABCG2Apical (brush border); cell into urine, ATP-drivenEstrone-3-sulfate, methotrexate, rosuvastatin, sulfasalazine (in vitro)Elacridar, Ko143, novobiocin (in vitro)
URAT1SLC22A12Apical; urine into cell (reabsorption)Urate, exchanged for lactate, nicotinate or chloride (UniProt)Not listed by FDA

FDA, Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, Tables 3-1 and 3-2 (content current June 5, 2023); FDA, Healthcare professionals: examples of drugs that interact with CYP enzymes and transporter systems, Table 1 (content current May 29, 2026); UniProt; Giacomini et al. 2010; Huls et al. 2008. The ITC notes that the membrane localization of some transporters is controversial. "In vitro" marks FDA's examples for laboratory studies; "clinical" marks drugs FDA lists from human interaction studies.

ICH M12 cutoffs below which a clinical transporter inhibition risk can be excluded
TransporterICH M12 cutoff to exclude clinical inhibition risk
OAT1, OAT3, OCT2IC50,u > 10 × Cmax,u (Cmax,u/IC50,u < 0.1)
MATE1, MATE2-KIC50,u > 50 × Cmax,u (Cmax,u/IC50,u < 0.02)
P-gp, BCRP (oral drugs)IC50,u > 0.1 × (Dose/250 mL)

ICH M12, Table 1. Cmax,u: unbound maximal plasma concentration of the inhibitor at steady state after the therapeutic dose. M12 also lists endogenous biomarkers: N1-methylnicotinamide and N1-methyladenosine for OCT2, MATE1 and MATE2-K, and pyridoxic acid for OAT1/3.

Creatinine is itself an OCT2 and MATE substrate, and drugs that inhibit its secretion can raise serum creatinine. KDIGO lists decreased tubular secretion among the non-GFR determinants of serum creatinine, which is why such a rise does not by itself show a fall in filtration.

Blocking a renal transporter cut the renal clearance of the second drug by a quarter to two thirds in clinical studiesPublished clinical data
Published decreases in renal clearance of seven drugs when given with probenecid, cimetidine or quinidineProbenecid → furosemide (OATs)Probenecid → furosemide (OATs): renal clearance down 66%−66%Probenecid → cidofovir (OATs)Probenecid → cidofovir (OATs): renal clearance down 32%−32%Probenecid → acyclovir (OATs)Probenecid → acyclovir (OATs): renal clearance down 32%−32%Cimetidine → metformin (OCTs)Cimetidine → metformin (OCTs): renal clearance down 27%−27%Cimetidine → dofetilide (OCTs)Cimetidine → dofetilide (OCTs): renal clearance down 33%−33%Cimetidine → pilsicainide (OCTs)Cimetidine → pilsicainide (OCTs): renal clearance down 28% to 41%−28 to −41%Quinidine → digoxin (P-gp)Quinidine → digoxin (P-gp): renal clearance down 34% to 48%−34 to −48%0−20%−40%−60%−80%Decrease in renal clearance of the affected drugPublished decreases in renal clearance of seven drugs when given with probenecid, cimetidine or quinidineProbenecid → furosemide (OATs)Probenecid → furosemide (OATs): renal clearance down 66%−66%Probenecid → cidofovir (OATs)Probenecid → cidofovir (OATs): renal clearance down 32%−32%Probenecid → acyclovir (OATs)Probenecid → acyclovir (OATs): renal clearance down 32%−32%Cimetidine → metformin (OCTs)Cimetidine → metformin (OCTs): renal clearance down 27%−27%Cimetidine → dofetilide (OCTs)Cimetidine → dofetilide (OCTs): renal clearance down 33%−33%Cimetidine → pilsicainide (OCTs)Cimetidine → pilsicainide (OCTs): renal clearance down 28% to 41%−28 to −41%Quinidine → digoxin (P-gp)Quinidine → digoxin (P-gp): renal clearance down 34% to 48%−34 to −48%0−20%−40%−60%−80%Decrease in renal clearance of the affected drug
Giacomini et al., Nat Rev Drug Discov 2010, Table 3 (selected transporter-mediated clinical drug–drug interactions, with the original studies cited there). The implicated transporter is the likely one; in vivo studies cannot assign a single transporter with certainty.
Show data: decreases in renal clearance
Clinical interactions and the reported change in renal clearance
Interacting drug → affected drugLikely transporterReported effect
Probenecid → furosemideOATsCLR −66%
Probenecid → cidofovirOATsCLR −32%
Probenecid → acyclovirOATsCLR −32%, AUC +40%
Cimetidine → metforminOCTsCLR −27%, AUC +50%
Cimetidine → dofetilideOCTsCLR −33%
Cimetidine → pilsicainideOCTsCLR −28% (AUC +33%) in one study, −41% in another
Quinidine → digoxinP-gpCLR −34% to −48%
Kidney function tests

Serum creatinine becomes an estimate of GFR only after age and sex enter the equation

Measuring GFR needs the plasma or urinary clearance of an exogenous marker such as iohexol, iothalamate or 51Cr-EDTA, usually with repeated blood samples, and is available only in certain centers. Laboratories instead report an estimated GFR (eGFR) calculated from a blood marker made by the body. KDIGO recommends a validated estimating equation over the serum marker alone, and advises against using race in the calculation.

Blood and urine tests of kidney function, what they measure and what besides GFR affects them
TestWhat it isAffected by more than GFR
Serum creatinineMade in muscle from creatine phosphate; filtered, not reabsorbed, and secreted in the late proximal nephron, so excretion runs about 10% above filtration. Adult reference excretion 1.7 g/day (male), 1.0 g/day (female)Muscle mass and diet (meat, high-protein diets, creatine supplements), tubular secretion and drugs that block it, extrarenal elimination. Men had 21% higher serum creatinine than women in a 9-year study of 144 subjects
Cystatin CA 120-amino-acid cysteine protease inhibitor found in plasma and other body fluids (UniProt P01034)Thought to be higher adiposity, smoking, hypo- and hyperthyroidism, glucocorticoid excess and chronic inflammation; less understood than for creatinine
Blood urea nitrogen (BUN)Urea nitrogen; the liver converts ammonia from protein breakdown into urea, which the kidneys excrete. About 60% of filtered urea reaches the urineHigher with dehydration, burns, some medicines, a high-protein diet or a recent heart attack; lower with low protein intake, malnutrition or liver disease. Levels vary with sex and usually rise with age
Urine albumin-to-creatinine ratio (ACR)Albumin in a urine sample divided by urine creatinine, in mg/g or mg/mmol; a marker of kidney damageNot a GFR test. KDIGO categories: A1 <30, A2 30–300 (moderately increased relative to the young adult level), A3 >300 mg/g

Creatinine and urea: ICRP Publication 89, paragraphs 397–400 and Table 2.42. Measured GFR and non-GFR determinants: KDIGO 2024 CKD guideline, Tables 7, 8 and 9 and chapter 1.2 text. Cystatin C protein: UniProt P01034 (146-residue precursor with a 26-residue signal peptide). BUN: MedlinePlus, BUN (Blood Urea Nitrogen) test, updated October 27, 2024. ACR: KDIGO 2024, Table 3. Numerical reference ranges vary by laboratory and are not given here.

The CKD-EPI 2021 creatinine equation, as published

eGFRcr = 142 × min(Scr/κ, 1)α × max(Scr/κ, 1)−1.200 × 0.9938Age × 1.012 [if female]

κ = 0.7 (female) or 0.9 (male); α = −0.241 (female) or −0.302 (male); Scr = serum creatinine in mg/dL (multiply µmol/L by 1/88.4); Age in years; eGFR in mL/min per 1.73 m² of body-surface area. There is no race coefficient.

Inker LA, Eneanya ND, Coresh J, et al., for the Chronic Kidney Disease Epidemiology Collaboration. New creatinine- and cystatin C–based equations to estimate GFR without race. N Engl J Med 2021;385:1737–1749, Table 2 ("2021 CKD-EPI creatinine": intercept 142; a1 F −0.241, M −0.302; a2 −1.200; age coefficient 0.9938; female 1.012) and its footnote formula. Conversion factor 88.4 µmol/L per mg/dL: the same paper and KDIGO 2024.

eGFRcr-cys = 135 × min(Scr/κ, 1)α × max(Scr/κ, 1)−0.544 × min(Scys/0.8, 1)−0.323 × max(Scys/0.8, 1)−0.778 × 0.9961Age × 0.963 [if female]

κ as above; α = −0.219 (female) or −0.144 (male); Scys = serum cystatin C in mg/L.

Inker et al. 2021, Table 2 ("2021 CKD-EPI creatinine–cystatin C"). In their validation set of 4,050 people, 85% or more of eGFR values were within 30% of measured GFR for every equation tested, and the new creatinine–cystatin C equations were more accurate than the new creatinine equations. KDIGO 2024 recommends eGFRcr-cys where eGFRcr is less accurate and GFR affects a clinical decision (Recommendation 1.2.2.1, grade 1C).

The same serum creatinine maps to a lower eGFR in women and at older agesCalculation
Estimated GFR against serum creatinine from the 2021 CKD-EPI creatinine equation for women and men aged 30, 50 and 70 years, over the KDIGO GFR categories G1 to G5G1G2G3aG3bG4G501530456090120150eGFR, mL/min/1.73 m2​0.511.522.533.54Serum creatinine, mg/dLWomen, age 30Women, age 50Women, age 70Men, age 30Men, age 50Men, age 70WomenMenage 30age 50age 70Bands: KDIGOGFR categoriesEstimated GFR against serum creatinine from the 2021 CKD-EPI creatinine equation for women and men aged 30, 50 and 70 years, over the KDIGO GFR categories G1 to G5G1G2G3aG3bG4G501530456090120150eGFR, mL/min/1.73 m2​0.511.522.533.54Serum creatinine, mg/dLWomen, age 30Women, age 50Women, age 70Men, age 30Men, age 50Men, age 70WomenMenage 30age 50age 70Bands: KDIGO GFR categories
Calculated from the 2021 CKD-EPI creatinine equation with the coefficients published by Inker et al., N Engl J Med 2021;385:1737–1749, Table 2. Background bands: KDIGO 2024 GFR categories. An educational calculation, not a measurement or a prediction for any person; it does not replace a laboratory report.
Show data: calculated eGFR, mL/min/1.73 m²
eGFR from the 2021 CKD-EPI creatinine equation at eight serum creatinine values for six age and sex groups
Serum creatinine, mg/dLWoman 30Man 30Woman 50Man 50Woman 70Man 70
0.612413310911897104
0.8102122901087995
1.07810469926181
1.2628355744965
1.5486442563750
2.0344530402635
3.0212818251622
4.0152013171115

For drug dosing, FDA asks that eGFR be converted from mL/min per 1.73 m² to mL/min with the person's body-surface area, because a drug's renal clearance follows the individual's own GFR.

Staging

KDIGO stages chronic kidney disease by GFR and albuminuria together

KDIGO defines chronic kidney disease (CKD) as abnormalities of kidney structure or function present for at least 3 months, with implications for health. Either a GFR below 60 mL/min/1.73 m² or a marker of kidney damage, such as an ACR of 30 mg/g or more, qualifies. CKD is classified by cause, GFR category (G1–G5) and albuminuria category (A1–A3).

Prognosis worsens down the GFR categories and across the albuminuria categoriesKDIGO 2024 classification
KDIGO 2024 prognosis of chronic kidney disease by GFR category G1 to G5 and albuminuria category A1 to A3: low, moderately increased, high or very high riskA1<30 mg/gNormal to mildly increasedA230–300 mg/gModerately increasedA3>300 mg/gSeverely increasedGFR category, mL/min/1.73 m2​G1Normal or high≥90G1, A1: Low riskLowG1, A2: Moderately increased riskModerateG1, A3: High riskHighG2Mildly decreased60–89G2, A1: Low riskLowG2, A2: Moderately increased riskModerateG2, A3: High riskHighG3aMildly to moderately decreased45–59G3a, A1: Moderately increased riskModerateG3a, A2: High riskHighG3a, A3: Very high riskVery highG3bModerately to severely decreased30–44G3b, A1: High riskHighG3b, A2: Very high riskVery highG3b, A3: Very high riskVery highG4Severely decreased15–29G4, A1: Very high riskVery highG4, A2: Very high riskVery highG4, A3: Very high riskVery highG5Kidney failure<15G5, A1: Very high riskVery highG5, A2: Very high riskVery highG5, A3: Very high riskVery highLow risk applies only if there are no other markers of kidney disease (then no CKD).KDIGO 2024 prognosis of chronic kidney disease by GFR category G1 to G5 and albuminuria category A1 to A3: low, moderately increased, high or very high riskA1<30 mg/gA230–300 mg/gA3>300 mg/gGFR categorymL/min/1.73 m2​G1 ≥90G1, A1: Low riskLowG1, A2: Moderately increased riskModerateG1, A3: High riskHighG2 60–89G2, A1: Low riskLowG2, A2: Moderately increased riskModerateG2, A3: High riskHighG3a 45–59G3a, A1: Moderately increased riskModerateG3a, A2: High riskHighG3a, A3: Very high riskVery highG3b 30–44G3b, A1: High riskHighG3b, A2: Very high riskVery highG3b, A3: Very high riskVery highG4 15–29G4, A1: Very high riskVery highG4, A2: Very high riskVery highG4, A3: Very high riskVery highG5 <15G5, A1: Very high riskVery highG5, A2: Very high riskVery highG5, A3: Very high riskVery highLow risk applies only if there are no other markers of kidneydisease (then no CKD).
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105(4S):S117–S314, "KDIGO: Prognosis of CKD by GFR and albuminuria categories" (p. S126) and Tables 2–3. KDIGO colors the cells green, yellow, orange and red; this page uses its own palette and writes the category in each cell.
Show data: the KDIGO categories in text
KDIGO GFR categories with the risk category in each albuminuria category
GFR categoryGFR, mL/min/1.73 m²TermA1 (<30 mg/g)A2 (30–300 mg/g)A3 (>300 mg/g)
G1≥90Normal or highLowModerately increasedHigh
G260–89Mildly decreasedLowModerately increasedHigh
G3a45–59Mildly to moderately decreasedModerately increasedHighVery high
G3b30–44Moderately to severely decreasedHighVery highVery high
G415–29Severely decreasedVery highVery highVery high
G5<15Kidney failureVery highVery highVery high

Without evidence of kidney damage, neither G1 nor G2 meets the criteria for CKD. G2 "mildly decreased" and A2 "moderately increased" are relative to the young adult level.

FDA uses a separate classification only to enroll dedicated renal impairment studies of drugs: normal ≥90, mild 60 to <90, moderate 30 to <60, and severe impairment or kidney failure not on dialysis <30 mL/min. FDA states it is not meant for classifying kidney disease.

KDIGO 2024, Tables 1–3; FDA, Pharmacokinetics in Patients with Impaired Renal Function, March 2024, Table 1.

Hormones

The kidney also makes renin, erythropoietin and calcitriol

Renin starts a cascade that raises blood pressure and sodium retention. Juxtaglomerular cells at the tips of the afferent arterioles release it when perfusion pressure falls, when circulating or sympathetic-nerve catecholamines stimulate their β-adrenergic receptors, or when the macula densa detects less NaCl. Angiotensin II then acts directly on vascular smooth muscle as a vasoconstrictor and stimulates aldosterone release from the adrenal cortex.

Renin starts a chain that ends with sodium retention in the collecting ductSchematic of published pathway
Renin from juxtaglomerular cells cuts angiotensinogen to angiotensin I; ACE makes angiotensin II, which constricts blood vessels and stimulates aldosterone release; aldosterone increases sodium reabsorption and potassium secretion through ENaC in the collecting ductRenin release rises witha fall in afferent arteriole pressure; β-adrenergic stimulationby catecholamines; low NaCl at the macula densaAngiotensinogenmade by the liverAngiotensin IAngiotensin IIreninEC 3.4.23.15ACEEC 3.4.15.1from juxtaglomerular cellsVasoconstrictionvascular smoothmuscleAldosteroneadrenal zona glomerulosa, CYP11B2Collecting ductmore Na+​ reabsorbed through ENaC; K+​ secretedRenin-angiotensin-aldosterone cascade, top to bottomRenin release rises witha fall in afferent arteriole pressure; β-adrenergicstimulation by catecholamines; low NaCl at the maculadensaAngiotensinogenmade by the liverAngiotensin IAngiotensin IIAldosteroneadrenal zona glomerulosa, CYP11B2; angiotensin II is alsoa direct vasoconstrictorCollecting ductmore Na+​ reabsorbed by ENaC; K+​ secretedrenin (juxtaglomerular cells), EC 3.4.23.15ACE, EC 3.4.15.1stimulates releaseacts on
Renin release: Yamaguchi H, Gomez RA, Sequeira-Lopez MLS. Hypertension 2023;80:1580–1589. Enzymes, angiotensin II actions and aldosterone synthesis: UniProt P00797 (renin, EC 3.4.23.15), P12821 (ACE, EC 3.4.15.1), P01019 (angiotensinogen, expressed by the liver), P19099 (CYP11B2, zona glomerulosa). ENaC and aldosterone: Gembillo et al. 2026.
Text version of the cascade

Angiotensinogen (from the liver) is cut by renin to angiotensin I, which angiotensin-converting enzyme (ACE) converts to angiotensin II. Angiotensin II acts on angiotensin receptors (AGTR1 and AGTR2) as a direct vasoconstrictor and stimulates the zona glomerulosa of the adrenal cortex to make aldosterone. Aldosterone increases sodium reabsorption through ENaC and potassium secretion in the connecting tubule and collecting duct.

Three hormones made by the kidney: cells of origin, stimulus and action
HormoneMade byMain stimulusWhat it does
Renin (enzyme, EC 3.4.23.15)Juxtaglomerular cells at the tips of the afferent arteriolesFall in perfusion pressure; β-adrenergic stimulation; low NaCl at the macula densaCuts angiotensinogen to angiotensin I, its only known function, starting the cascade above
Erythropoietin (EPO)Peritubular interstitial fibroblasts of the kidney, the primary source in adults; the liver is the main site during embryonic developmentHypoxia, through hypoxia-inducible factors (HIF)Binds its receptor EPOR to drive red blood cell production; inadequate EPO production contributes to the anemia of chronic kidney disease
Calcitriol (1α,25-dihydroxyvitamin D3)The kidney, by 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1, EC 1.14.15.18)Regulation not covered on this pageThe hormonally active form of vitamin D; acts through the vitamin D receptor in calcium and phosphorus homeostasis

Yamaguchi et al. 2023; UniProt P00797, P01588 (EPO), O15528 (CYP27B1), retrieved October 29, 2026; Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 2013;27:41–53; ICRP Publication 89, paragraph 334 (the kidney's two endocrine functions, calcitriol and erythropoietin).

Supplements and the kidney

Five supplement links to the kidney documented in people

Each item below rests on human data or on an agency statement. Some change a kidney test without a change in measured GFR; others are documented harms. None of this is advice about whether to take a supplement.

Creatine can raise serum creatinine without lowering measured GFR

KDIGO's table of indications for cystatin C lists high-protein diets and creatine supplements as non-GFR determinants of serum creatinine, noting minimal data. In a 20-year-old man with a single kidney who took creatine (20 g/day for 5 days, then 5 g/day for 30 days) on a high-protein diet, serum creatinine rose while 51Cr-EDTA clearance did not change. A 12-week randomized, placebo-controlled trial in people with type 2 diabetes found no significant difference in 51Cr-EDTA clearance between creatine and placebo.

Creatine supplementation case: serum creatinine, measured GFR and a calculated eGFR before and after
MeasureBeforeAfter 35 days
Serum creatinine, mg/dL1.031.27
Measured GFR, 51Cr-EDTA clearance, mL/min/1.73 m²81.682.0
eGFR from serum creatinine, CKD-EPI 2021 (calculated on this page)106.682.9

KDIGO 2024, Table 8; Gualano B, et al. Am J Kidney Dis 2010;55:e7–e9 (case report); Gualano B, et al. Eur J Appl Physiol 2011;111:749–756 (randomized trial; 51Cr-EDTA clearance difference −0.3 mL/min/1.73 m², 95% CI −24.9 to 24.2); Williamson L, New D. BMJ Case Rep 2014 (creatine ethyl ester raised serum creatinine in the absence of kidney pathology; it reversed after stopping). The eGFR row is an educational calculation from the published inputs (male, age 20), not a value reported by the authors. Related: Creatine.

Vitamin C intake was linked to more kidney stones in men

In three U.S. cohorts followed for a median 11.3 to 11.7 years, 6,245 incident kidney stones occurred. Higher total and supplemental vitamin C intake was associated with higher stone risk in men, not in women; dietary vitamin C was not associated in either. The authors lacked stone composition for all cases. NIH's Office of Dietary Supplements notes that high intakes can raise urinary oxalate and that the best evidence of a role in stone formation is in people with pre-existing hyperoxaluria.

In men, stone risk rose to a hazard ratio of 1.43 at total vitamin C intakes of 1,000 mg/day or morePublished cohort data
Hazard ratios for incident kidney stones in men by vitamin C intake, Health Professionals Follow-up StudyTotal <90 mg/d (reference)1.00Total 90–249 mg/dTotal 90–249 mg/d: HR 1.19 (95% CI 0.99–1.46)1.19 (0.99–1.46)Total 250–499 mg/dTotal 250–499 mg/d: HR 1.15 (95% CI 0.93–1.42)1.15 (0.93–1.42)Total 500–999 mg/dTotal 500–999 mg/d: HR 1.29 (95% CI 1.04–1.60)1.29 (1.04–1.60)Total ≥1,000 mg/dTotal ≥1,000 mg/d: HR 1.43 (95% CI 1.15–1.79)1.43 (1.15–1.79)Supplemental ≥1,000 mg/d vs noneSupplemental ≥1,000 mg/d vs none: HR 1.19 (95% CI 1.01–1.40)1.19 (1.01–1.40)0.811.251.52Hazard ratio (95% CI), log scaleHazard ratios for incident kidney stones in men by vitamin C intake, Health Professionals Follow-up StudyTotal <90 mg/d (reference)1.00Total 90–249 mg/dTotal 90–249 mg/d: HR 1.19 (95% CI 0.99–1.46)1.19 (0.99–1.46)Total 250–499 mg/dTotal 250–499 mg/d: HR 1.15 (95% CI 0.93–1.42)1.15 (0.93–1.42)Total 500–999 mg/dTotal 500–999 mg/d: HR 1.29 (95% CI 1.04–1.60)1.29 (1.04–1.60)Total ≥1,000 mg/dTotal ≥1,000 mg/d: HR 1.43 (95% CI 1.15–1.79)1.43 (1.15–1.79)Supplemental ≥1,000 mg/d vs noneSupplemental ≥1,000 mg/d vs none: HR 1.19 (95% CI 1.01–1.40)1.19 (1.01–1.40)0.811.251.52Hazard ratio (95% CI), log scale
Ferraro PM, Curhan GC, Gambaro G, Taylor EN. Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones. Am J Kidney Dis 2016;67:400–407 (40,536 men in the Health Professionals Follow-up Study; multivariable-adjusted; P for trend 0.005 for total and 0.001 for supplemental intake). An association in an observational cohort, not proof of cause.
Show data: hazard ratios in men
Hazard ratios for incident kidney stones in men by vitamin C intake
Vitamin C intakeHazard ratio (95% CI)
Total <90 mg/day1.00 (reference)
Total 90–249 mg/day1.19 (0.99–1.46)
Total 250–499 mg/day1.15 (0.93–1.42)
Total 500–999 mg/day (median ≈700)1.29 (1.04–1.60)
Total ≥1,000 mg/day1.43 (1.15–1.79)
Supplemental ≥1,000 mg/day vs no use1.19 (1.01–1.40)

Ferraro et al. 2016; NIH Office of Dietary Supplements, Vitamin C fact sheet for health professionals, updated July 31, 2025 (adult UL 2,000 mg/day). Related: Vitamin C.

Aristolochic acid can cause kidney failure and urothelial cancer

In Belgium, slimming pills dispensed by one clinic in 1990–1992 contained Aristolochia fangchi in place of Stephania tetrandra. FDA's May 31, 2000 letter reported over 100 patients with nephropathy and at least 70 who needed a kidney transplant or dialysis. Among 39 patients with end-stage disease who had their native kidneys and ureters removed, 18 had urothelial carcinoma (46%; 95% CI 29–62%).

Regulatory and hazard classifications of aristolochic acid
BodyStatementDate
FDA, letter to health care professionalsConcern about botanical products, including dietary supplements, containing aristolochic acid; names Aristolochia, Asarum, Bragantia, Stephania, Clematis, Akebia, Cocculus, Diploclisia, Menispermum and Sinomenium, and trade names such as Mu tong and Fang jiMay 31, 2000 (attachments updated April 2001)
FDA Import Alert 54-10Detention without physical examination of dietary supplements containing aristolochic acid; "a potent carcinogen and nephrotoxin"Published December 10, 2020
IARC Monographs Volume 100AAristolochic acid and plants containing aristolochic acid: carcinogenic to humans (Group 1)2012

Nortier JL, et al. N Engl J Med 2000;342:1686–1692; FDA, Letter to Health Care Professionals: FDA Concerned About Botanical Products, Including Dietary Supplements, Containing Aristolochic Acid, May 31, 2000 (archived copy); FDA Import Alert 54-10; IARC Monographs Volume 100A, Plants Containing Aristolochic Acid, section 5. More: Contaminants · Lessons learned.

Potassium and magnesium accumulate when the kidneys cannot excrete them

NIH's Office of Dietary Supplements states that the potassium intake recommendations do not apply to people whose potassium excretion is impaired by kidney disease or by medicines. Potassium-sparing diuretics, ACE inhibitors and angiotensin receptor blockers reduce urinary potassium excretion and can cause hyperkalemia, and experts recommend monitoring potassium in people taking them, especially with impaired kidney function. In people with normal kidney function, ODS reports no evidence that high potassium intakes cause hyperkalemia.

The kidneys largely control magnesium balance and excrete about 120 mg per day in urine. ODS states that the risk of magnesium toxicity rises with impaired renal function or kidney failure, because the ability to remove excess magnesium is reduced or lost. Very large doses of magnesium-containing laxatives and antacids, typically above 5,000 mg/day, have been associated with magnesium toxicity. The adult upper level for supplemental magnesium is 350 mg/day.

NIH Office of Dietary Supplements, Potassium fact sheet for health professionals, updated June 2, 2022; Magnesium fact sheet for health professionals, updated January 6, 2026. Related: Potassium · Magnesium.

Licorice lowers plasma potassium by blocking the inactivation of cortisol

Glycyrrhetic acid, from the glycyrrhizinic acid in licorice root, inhibits 11β-hydroxysteroid dehydrogenase type 2, the enzyme that inactivates cortisol to cortisone. Cortisol then occupies mineralocorticoid receptors, causing sodium and water retention and potassium loss, with renin and aldosterone suppressed. This pseudohyperaldosteronism can show as edema, hypokalemia and raised blood pressure.

A meta-analysis of 18 studies (337 participants) taking at least 100 mg of glycyrrhizic acid daily found a mean fall in plasma potassium of 0.33 mmol/L, a rise in systolic blood pressure of 5.45 mm Hg (95% CI 3.51–7.39), and falls in plasma renin activity and aldosterone. The European Scientific Committee on Food set 100 mg/day as an upper limit for regular ingestion and noted it may not protect people with hypertension or reduced enzyme activity. NCCIH states that even small amounts of glycyrrhizin from licorice root products have been linked to severe adverse effects in people with hypertension or with heart or kidney conditions.

European Commission, Scientific Committee on Food. Opinion on glycyrrhizinic acid and its ammonium salt, SCF/CS/ADD/EDUL/225 Final, April 10, 2003; Penninkilampi R, Eslick EM, Eslick GD. J Hum Hypertens 2017;31:699–707; NCCIH, Licorice Root, last updated April 2025. Related: Licorice root.

Related

Where these topics continue

Related pages: ADME, PK and PBPK (pharmacokinetic equations, PBPK structure, organ blood flows) · Contaminants · Lessons learned · Creatine · Vitamin C · Potassium · Magnesium · Licorice root · Sodium and electrolytes

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.